UCB’s Cimzia Could Be Delayed Until 2008 Or Later For Crohn’s
This article was originally published in The Pink Sheet Daily
Executive Summary
A key regulatory concern for the biologic is a lack of induction evaluation criteria in one of two pivotal Crohn’s trials, the firm tells “The Pink Sheet” DAILY.